Ensysce Biosciences (ENSC) Long-Term Deferred Tax (2019 - 2022)
Ensysce Biosciences (ENSC) posted quarterly Long-Term Deferred Tax of $82819.0 for Q2 2022, up 75190.0% quarter-over-quarter from $110.0 in Q1 2019.
Ensysce Biosciences (ENSC) Long-Term Deferred Tax (2019 - 2022) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Long-Term Deferred Tax for 2 consecutive years, with $82819.0 the latest figure, recorded in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 82,819.00 |
| Mar 31, 2019 | 110.00 |